FOUNDATIONONE®CDx

PATIENT	TUMOR TYPE	REPORT DATE
Yeh, Jung-Hui	Liver cholangiocarcinoma	29 Dec 2021
	COUNTRY CODE	ORDERED TEST #
	TW	ORD-1256018-01

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT
DISEASE Liver cholangiocarcinoma
NAME Yeh, Jung-Hui
DATE OF BIRTH 15 October 1948
SEX Male
MEDICAL RECORD # 36563436

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN SITE Liver
SPECIMEN ID S110-62229 A (PF21065)
SPECIMEN TYPE Slide Deck
DATE OF COLLECTION 29 November 2021
SPECIMEN RECEIVED 15 December 2021

Biomarker Findings
Microsatellite status - MS-Stable
Tumor Mutational Burden - 3 Muts/Mb

Genomic Findings
For a complete list of the genes assayed, please refer to the Appendix.

IDH1 R132C
PBRM1 S934fs*74

1 Disease relevant genes with no reportable alterations: *FGFR2*

† See About the Test in appendix for details.

Report Highlights

- Targeted therapies with NCCN categories of evidence in this tumor type: Ivosidenib (p. 4)

- Evidence-matched clinical trial options based on this patient's genomic findings: (p. 5)

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS	
Microsatellite status - MS-Stable	No therapies or clinical trials. see Biomarker Findings section	
Tumor Mutational Burden - 3 Muts/Mb	No therapies or clinical trials. see Biomarker Findings section	
GENOMIC FINDINGS	THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
IDH1 - R132C	Ivosidenib 2A	none
10 Trials *see p. 5*		

☐ *NCCN category*

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

PBRM1 - S934fs*74 .... p. 3

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

PATIENT
Yeh, Jung-Hui

TUMOR TYPE
Liver cholangiocarcinoma

REPORT DATE
29 Dec 2021

ORDERED TEST # ORD-1256018-01

BIOMARKER
Microsatellite status

RESULT
MS-Stable

POTENTIAL TREATMENT STRATEGIES
— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors[1-3], including approved therapies nivolumab and pembrolizumab[4]. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)[5].

FREQUENCY & PROGNOSIS

MSI-H is infrequent in cholangiocarcinoma, reported in 1% of samples[6]. A non-zero level of MSI has been reported in 18-49% of cholangiocarcinoma cases[7-10], although the studies did not specify what fraction of cases were MSI-H. A higher frequency of MSI (63%) was reported in patients with intrahepatic cholangiocarcinoma associated with exposure to Thorotrast[9]. One study reported that MSI is associated with poor prognosis in liver fluke-related cholangiocarcinoma[8].

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor[11]. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2[11-13]. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers[14-16]. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins[11,13,15-16].

BIOMARKER
Tumor Mutational Burden

RESULT
3 Muts/Mb

POTENTIAL TREATMENT STRATEGIES
— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[17-19], anti-PD-1 therapies[17-20], and combination nivolumab and ipilimumab[21-26]. In multiple pan-tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors[17-20,27]. Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors[17]. Analyses across several solid tumor types reported that patients with higher TMB (defined as ≥16-20 Muts/Mb) achieved greater clinical benefit from PD-1 or PD-L1-targeting monotherapy, compared with patients with higher TMB treated with chemotherapy[28] or those with lower TMB treated with PD-1 or PD-L1-targeting agents[18]. However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB ≥10 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials[20,27]. Together, these studies suggest that patients with TMB ≥10 Muts/Mb may derive clinical benefit from PD-1 or PD-L1 inhibitors.

FREQUENCY & PROGNOSIS

Cholangiocarcinoma harbors a median TMB of 2.5 mutations per megabase (muts/Mb), and 1.9% of cases have high TMB (>20 muts/Mb)[29]. Although cases with hypermutated biliary tract cancer were enriched in a subgroup with poor prognosis in 1 study[30], TMB-high (≥10 mut/Mb) status in biliary adenocarcinoma not treated with immunotherapy was not significantly associated with OS in another study, in which patients with TMB-high tumors experienced numerically longer OS compared with patients with TMB-low tumors (11.5 vs. 8.4 months, adjusted HR=0.65)[31].

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[32-33] and cigarette smoke in lung cancer[34-35], treatment with temozolomide-based chemotherapy in glioma[36-37], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[38-42], and microsatellite instability (MSI)[38,41-42]. This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD-1- or PD-L1-targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types[18-19,27].

FOUNDATIONONE®CDx

PATIENT
Yeh, Jung-Hui

TUMOR TYPE
Liver cholangiocarcinoma

REPORT DATE
29 Dec 2021

GENOMIC FINDINGS

ORDERED TEST # ORD-1256018-01

GENE
IDH1

ALTERATION
R132C

TRANSCRIPT ID
NM_005896

CODING SEQUENCE EFFECT
394C>T

VARIANT ALLELE FREQUENCY (% VAF)
16.6%

POTENTIAL TREATMENT STRATEGIES
— Targeted Therapies —

IDH1 mutations that lead to production of 2-HG, most commonly R132 alterations, may predict sensitivity to IDH1-mutation-specific inhibitors such as ivosidenib[43]. A Phase 1b/2 study of the IDH1 inhibitor olutasidenib for patients with IDH1-mutated glioma reported a DCR of 50% (n=24) with 1 PR[44]. A Phase 1 study of the pan-IDH1/IDH2 inhibitor vorasidenib for patients with IDH1- or IDH2-mutated glioma reported an ORR of 18.2% (4/22; RANO criteria) and median PFS of 31.4 months for non-enhancing cases and median PFS of 7.5 months for the overall glioma population (n=52)[45]. Preclinical studies suggested that IDH1 neomorphic mutations may also confer sensitivity to PARP inhibitors[46-49].

FREQUENCY & PROGNOSIS

IDH1 or IDH2 mutation has been reported in 10-23% of cholangiocarcinoma cases and has been found to be more prevalent in intrahepatic (22-28%) than extrahepatic (0-7%) cholangiocarcinomas[50-55]. In patients with intrahepatic cholangiocarcinoma, IDH1/2 mutations are associated with longer OS and increased time to tumor recurrence[55]. A preclinical study observed that mutant IDH can block hepatocyte differentiation and cooperate with oncogenic KRAS to drive cholangiocarcinoma development[56].

FINDING SUMMARY

The isocitrate dehydrogenases IDH1 and IDH2 encode highly homologous enzymes that are involved in the citric acid (TCA) cycle and other metabolic processes, playing roles in normal cellular metabolism and in protection against oxidative stress and apoptosis[57]. R132 is located within the active site of IDH1 and is a hotspot for mutations in cancer[57-61]. Substitutions at IDH1 R132 alter the enzymatic activity of IDH1, resulting in the production of the oncometabolite, D-2-hydroxyglutarate (2-HG)[59-63], which promotes tumorigenesis[59,64-67].

GENE
PBRM1

ALTERATION
S934fs*74

TRANSCRIPT ID
NM_018313

CODING SEQUENCE EFFECT
2800delT

VARIANT ALLELE FREQUENCY (% VAF)
21.6%

POTENTIAL TREATMENT STRATEGIES
— Targeted Therapies —

On the basis of significant clinical data from prospective studies, PBRM1 inactivation may predict benefit from PD-1-targeting immune checkpoint inhibitors, such as nivolumab, pembrolizumab, cemiplimab, or dostarlimab, for patients with clear cell renal cell carcinoma and prior anti-angiogenic therapy[68-70]. However, multiple retrospective analyses report that PBRM1 mutation status is not associated with clinical benefit from various immune checkpoint inhibitors in other solid tumor types, including non-small cell lung cancer, urothelial carcinoma, melanoma, or esophagogastric cancer, suggesting that the impact of PBRM1 loss of function may depend on tumor type[71-74].

FREQUENCY & PROGNOSIS

Somatic mutations in PBRM1 are prevalent in clear cell renal cell carcinomas (ccRCC) (41%)[75], intrahepatic cholangiocarcinomas (9-13%)[76-79], and bladder urothelial carcinomas (6-14%)[80-82]. PBRM1 mutations are detected in other tumor types, including in 37% (11/30) of papillary meningiomas and 4% (2/54) of thymic carcinomas[83-84] and in skin (6%), large intestine (5%), stomach (5%), soft tissue (3%), and lung (2%) (COSMIC, 2021)[85]. Preclinical studies have shown that loss of PBRM1 increases the proliferation of ccRCC cell lines[75]. PBRM1 protein loss or mutation is correlated with late tumor stage, low differentiation grade, and/or poor patient prognosis in ccRCC[86-88], extrahepatic cholangiocarcinoma[78], and pancreatic cancer[89]. However, one ccRCC study reported no correlation between PBRM1 mutation and cancer-specific survival[90]. In ccRCC, PBRM1 alterations are generally observed to be mutually exclusive with BAP1 alterations[75,91]; a retrospective analysis of 145 primary ccRCCs found a decreased median overall survival for patients with mutations in both BAP1 and PBRM1 compared with patients having either mutated gene alone[92]. A trend toward worse survival was also seen in patients with intrahepatic cholangiocarcinoma harboring mutations in chromatin modifiers (including BAP1, ARID1A, or PBRM1)[77].

FINDING SUMMARY

PBRM1 (Polybromo-1), also known as BAF180, encodes a subunit of ATP-dependent chromatin-remodeling complexes and a required cofactor for ligand-dependent transactivation by nuclear hormone receptors[93]. Mutation, loss, or inactivation of PBRM1 has been reported in several cancers, suggesting PBRM1 is a tumor suppressor[75,77,94]. Alterations such as seen here may disrupt PBRM1 function or expression[95-100].

FOUNDATIONONE®CDx

PATIENT
Yeh, Jung-Hui

TUMOR TYPE
Liver cholangiocarcinoma

REPORT DATE
29 Dec 2021

ORDERED TEST # ORD-1256018-01

Ivosidenib

Assay findings association

IDH1
R132C

AREAS OF THERAPEUTIC USE

Ivosidenib is an isocitrate dehydrogenase 1 (IDH1) inhibitor that is FDA approved to treat patients with a susceptible IDH1 mutation in relapsed or refractory acute myeloid leukemia (AML) or previously treated locally advanced or metastatic cholangiocarcinoma. It is also approved as a first-line treatment for patients with AML and a susceptible IDH1 mutation who are not eligible for intensive induction chemotherapy or who are ≥75 years old. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of extensive clinical evidence in AML[101] and cholangiocarcinoma[102-103] and limited clinical data in myelodysplastic syndrome (MDS)[101] and glioma[43,104],

IDH1 R132 mutation may confer sensitivity to ivosidenib.

SUPPORTING DATA

In the Phase 3 ClarIDHy trial for patients with previously treated IDH1 R132-mutated cholangiocarcinoma, ivosidenib significantly increased PFS (2.7 vs. 1.4 months, HR=0.37, p <0.001) as well as PFS rates compared with placebo (6-month: 32% vs. 0%, 12-month: 22% vs. 0%) and reported numerically increased OS (10.3 vs. 7.5 months, HR=0.79, p=0.09), which reached statistical significance once adjusted for crossover (10.3 vs. 5.1 months, HR=0.49, p <0.0001)[103,105] . A Phase 1 study reported an ORR of 5.6% (4/72, all PRs), SD rate of 56% (40/72), median PFS of 3.8 months, and median OS of 13.8 months for patients with IDH1-mutated cholangiocarcinoma treated with ivosidenib[102].

NOTE Genomic alterations detected may be associated with activity of certain FDA approved drugs, however, the agents listed in this report may have varied evidence in the patient's tumor type.

FOUNDATIONONE®CDx

PATIENT
Yeh, Jung-Hui

TUMOR TYPE
Liver cholangiocarcinoma

REPORT DATE
29 Dec 2021

ORDERED TEST # ORD-1256018-01

CLINICAL TRIALS

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or visit https://www.foundationmedicine.com/genomic-testing#support-services.

GENE
IDH1

ALTERATION
R132C

RATIONALE
IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors.

NCT02264678	**PHASE 1/2**
Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents	**TARGETS** ATR, PARP, PD-L1

LOCATIONS: Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California

NCT04298021	**PHASE 2**
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer	**TARGETS** PD-L1, ATR, PARP

LOCATIONS: Seoul (Korea, Republic of)

NCT03772561	**PHASE 1**
Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies	**TARGETS** PARP, AKTs, PD-L1

LOCATIONS: Singapore (Singapore)

NCT04801966	**PHASE NULL**
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study	**TARGETS** CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT04497116	**PHASE 1/2**
Study of RP-3500 in Advanced Solid Tumors	**TARGETS** ATR, PARP

LOCATIONS: Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee, Texas

ORDERED TEST # ORD-1256018-01

CLINICAL TRIALS

NCT03907969
PHASE 1/2

A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers

TARGETS
PARP, DNA-PK

LOCATIONS: Newcastle upon Tyne (United Kingdom), London (United Kingdom), Connecticut, Texas

---

NCT03878095
PHASE 2

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

TARGETS
ATR, PARP

LOCATIONS: Utah, Wisconsin, Michigan, Ohio, Connecticut, Maryland, Texas, Florida

---

NCT03830918
PHASE 1/2

Niraparib and Temozolomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

TARGETS
PARP

LOCATIONS: California

NCT03212274
PHASE 2

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

TARGETS
PARP

LOCATIONS: California, Wisconsin, Missouri, Kansas

NCT03221400
PHASE 1/2

PEN-866 in Patients With Advanced Solid Malignancies

TARGETS
PARP, HSP90

LOCATIONS: Nevada, Colorado, Michigan, Oklahoma, Arkansas, Tennessee, Pennsylvania, Maryland, Virginia

---

FOUNDATION**ONE**®CDx

PATIENT
Yeh, Jung-Hui

TUMOR TYPE
Liver cholangiocarcinoma

REPORT DATE
29 Dec 2021

ORDERED TEST # ORD-1256018-01

APPENDIX | Variants of Unknown Significance

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

BARD1 I258V	**CDKN2A/B** R73G	**DDR2** amplification	**HSD3B1** amplification
IRS2 G1312S	**MYCL1** Y43C	**NOTCH2** amplification	**NTRK1** P397T and R220W
POLE H1810L	**TEK** Y1024F		

FOUNDATION**ONE**®CDx

PATIENT
Yeh, Jung-Hui

TUMOR TYPE
Liver cholangiocarcinoma

REPORT DATE
29 Dec 2021

ORDERED TEST # ORD-1256018-01

APPENDIX Genes Assayed in FoundationOne®CDx

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	ACVR1B	AKT1	AKT2	AKT3	ALK	ALOX12B	AMER1 (FAM123B)	APC
AR	ARAF	ARFRP1	ARID1A	ASXL1	ATM	ATR	ATRX	AURKA
AURKB	AXIN1	AXL	BAP1	BARD1	BCL2	BCL2L1	BCL2L2	BCL6
BCOR	BCORL1	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2
BTK	C11orf30 (EMSY)	C17orf39 (GID4)	CALR	CARD11	CASP8	CBFB	CBL	CCND1
CCND2	CCND3	CCNE1	CD22	CD274 (PD-L1)	CD70	CD79A	CD79B	CDC73
CDH1	CDK12	CDK4	CDK6	CDK8	CDKN1A	CDKN1B	CDKN2A	CDKN2B
CDKN2C	CEBPA	CHEK1	CHEK2	CIC	CREBBP	CRKL	CSF1R	CSF3R
CTCF	CTNNA1	CTNNB1	CUL3	CUL4A	CXCR4	CYP17A1	DAXX	DDR1
DDR2	DIS3	DNMT3A	DOT1L	EED	EGFR	EP300	EPHA3	EPHB1
EPHB4	ERBB2	ERBB3	ERBB4	ERCC4	ERG	ERRFI1	ESR1	EZH2
FAM46C	FANCA	FANCC	FANCG	FANCL	FAS	FBXW7	FGF10	FGF12
FGF14	FGF19	FGF23	FGF3	FGF4	FGF6	FGFR1	FGFR2	FGFR3
FGFR4	FH	FLCN	FLT1	FLT3	FOXL2	FUBP1	GABRA6	GATA3
GATA4	GATA6	GNA11	GNA13	GNAQ	GNAS	GRM3	GSK3B	H3F3A
HDAC1	HGF	HNF1A	HRAS	HSD3B1	ID3	IDH1	IDH2	IGF1R
IKBKE	IKZF1	INPP4B	IRF2	IRF4	IRS2	JAK1	JAK2	JAK3
JUN	KDM5A	KDM5C	KDM6A	KDR	KEAP1	KEL	KIT	KLHL6
KMT2A (MLL)	KMT2D (MLL2)	KRAS	LTK	LYN	MAF	MAP2K1 (MEK1)	MAP2K2 (MEK2)	MAP2K4
MAP3K1	MAP3K13	MAPK1	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1
MERTK	MET	MITF	MKNK1	MLH1	MPL	MRE11A	MSH2	MSH3
MSH6	MST1R	MTAP	MTOR	MUTYH	MYC	MYCL (MYCL1)	MYCN	MYD88
NBN	NF1	NF2	NFE2L2	NFKBIA	NKX2-1	NOTCH1	NOTCH2	NOTCH3
NPM1	NRAS	NSD3 (WHSC1L1)	NT5C2	NTRK1	NTRK2	NTRK3	P2RY8	PALB2
PARK2	PARP1	PARP2	PARP3	PAX5	PBRM1	PDCD1 (PD-1)	PDCD1LG2 (PD-L2)	PDGFRA
PDGFRB	PDK1	PIK3C2B	PIK3C2G	PIK3CA	PIK3CB	PIK3R1	PIM1	PMS2
POLD1	POLE	PPARG	PPP2R1A	PPP2R2A	PRDM1	PRKAR1A	PRKCI	PTCH1
PTEN	PTPN11	PTPRO	QKI	RAC1	RAD21	RAD51	RAD51B	RAD51C
RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	REL	RET
RICTOR	RNF43	ROS1	RPTOR	SDHA	SDHB	SDHC	SDHD	SETD2
SF3B1	SGK1	SMAD2	SMAD4	SMARCA4	SMARCB1	SMO	SNCAIP	SOCS1
SOX2	SOX9	SPEN	SPOP	SRC	STAG2	STAT3	STK11	SUFU
SYK	TBX3	TEK	TET2	TGFBR2	TIPARP	TNFAIP3	TNFRSF14	TP53
TSC1	TSC2	TYRO3	U2AF1	VEGFA	VHL	WHSC1	WT1	XPO1
XRCC2	ZNF217	ZNF703						

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	BCL2	BCR	BRAF	BRCA1	BRCA2	CD74	EGFR	ETV4
ETV5	ETV6	EWSR1	EZR	FGFR1	FGFR2	FGFR3	KIT	KMT2A (MLL)
MSH2	MYB	MYC	NOTCH2	NTRK1	NTRK2	NUTM1	PDGFRA	RAF1
RARA	RET	ROS1	RSPO2	SDC4	SLC34A2	TERC*	TERT**	TMPRSS2

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

FOUNDATIONONE®CDx

PATIENT
Yeh, Jung-Hui

TUMOR TYPE
Liver cholangiocarcinoma

REPORT DATE
29 Dec 2021

ORDERED TEST # ORD-1256018-01

APPENDIX   About FoundationOne®CDx

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium.

ABOUT FOUNDATIONONE CDX
FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details: www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE
FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLES
FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture–selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g.,gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT
Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance
FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)
An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for ERBB2 and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials
Ranking of Therapies in Summary Table
Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials
Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION
Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations
1. In the fractional-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-

FOUNDATIONONE®CDx

PATIENT
Yeh, Jung-Hui

TUMOR TYPE
Liver cholangiocarcinoma

REPORT DATE
29 Dec 2021

ORDERED TEST # ORD-1256018-01

APPENDIX   About FoundationOne®CDx

Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.

2. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.

3. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.

4. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.

5. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.

6. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/ report the frequency of HER2 overexpression as 20% in breast cancer. Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	%CV*
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

*Interquartile Range = 1st Quartile to 3rd Quartile

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, CBL, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear

FOUNDATIONONE®CDx

PATIENT
Yeh, Jung-Hui

TUMOR TYPE
Liver cholangiocarcinoma

REPORT DATE
29 Dec 2021

ORDERED TEST # ORD-1256018-01

APPENDIX   About FoundationOne®CDx

cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 5.2.0

The median exon coverage for this sample is 769x

FOUNDATIONONE®CDx

PATIENT
Yeh, Jung-Hui

TUMOR TYPE
Liver cholangiocarcinoma

REPORT DATE
29 Dec 2021

ORDERED TEST # ORD-1256018-01

APPENDIX   References

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250
3. Lal N, et al. Oncoimmunology (2015) pmid: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Javle et al., 2019; ASCO Abstract 4087
7. Momoi H, et al. J. Hepatol. (2001) pmid: 11580146
8. Limpaiboon T, et al. Cancer Lett. (2002) pmid: 12175538
9. Liu D, et al. Int. J. Cancer (2002) pmid: 12402306
10. Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736
11. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942
12. You JF, et al. Br. J. Cancer (2010) pmid: 21081928
13. Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249
14. Boland CR, et al. Cancer Res. (1998) pmid: 9823339
15. Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785
16. Boland CR, et al. Gastroenterology (2010) pmid: 20420947
17. Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254
18. Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386
19. Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947
20. Cristescu R, et al. Science (2018) pmid: 30309915
21. Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829
22. Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845
23. Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128
24. Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394
25. Rozeman EA, et al. Nat Med (2021) pmid: 33558721
26. Sharma P, et al. Cancer Cell (2020) pmid: 32916128
27. Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526
28. Legrand et al., 2018; ASCO Abstract 12000
29. Chalmers ZR, et al. Genome Med (2017) pmid: 28420421
30. Nakamura H, et al. Nat. Genet. (2015) pmid: 26258846
31. Shao C, et al. JAMA Netw Open (2020) pmid: 33119110
32. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
33. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
34. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
35. Rizvi NA, et al. Science (2015) pmid: 25765070
36. Johnson BE, et al. Science (2014) pmid: 24336570
37. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
38. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
39. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
40. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
41. Nature (2012) pmid: 22810696
42. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
43. Fan B, et al. Invest New Drugs (2019) pmid: 31028664
44. De La Fuente et al., 2020; ASCO Abstract 2505
45. Mellinghoff et al., 2020; ASCO Abstract 2504
46. Philip B, et al. Cell Rep (2018) pmid: 29719265
47. Molenaar RJ, et al. Clin. Cancer Res. (2018) pmid: 29339439
48. Lu Y, et al. Cancer Res. (2017) pmid: 28202508
49. Sulkowski PL, et al. Sci Transl Med (2017) pmid: 28148839
50. Voss JS, et al. Hum. Pathol. (2013) pmid: 23391413
51. Sia D, et al. Oncogene (2013) pmid: 23318457
52. Kipp BR, et al. Hum. Pathol. (2012) pmid: 22503487
53. Ross JS, et al. Oncologist (2014) pmid: 24563076
54. Borger DR, et al. Oncologist (2012) pmid: 22180306
55. Wang P, et al. Oncogene (2013) pmid: 22824796
56. Saha SK, et al. Nature (2014) pmid: 25043045
57. Reitman ZJ, et al. J. Natl. Cancer Inst. (2010) pmid: 20513808
58. Jin G, et al. PLoS ONE (2011) pmid: 21326614
59. Gross S, et al. J. Exp. Med. (2010) pmid: 20142433
60. Ward PS, et al. Cancer Cell (2010) pmid: 20171147
61. Leonardi R, et al. J. Biol. Chem. (2012) pmid: 22442146
62. Dang L, et al. Nature (2009) pmid: 19935646
63. Ward PS, et al. Oncogene (2012) pmid: 21996744
64. Figueroa ME, et al. Cancer Cell (2010) pmid: 21130701
65. Xu W, et al. Cancer Cell (2011) pmid: 21251613
66. Turcan S, et al. Nature (2012) pmid: 22343889
67. Duncan CG, et al. Genome Res. (2012) pmid: 22899282
68. Braun DA, et al. JAMA Oncol (2019) pmid: 31486842
69. Braun DA, et al. Nat Med (2020) pmid: 32472114
70. Miao D, et al. Science (2018) pmid: 29301960
71. Abou Alaiwi S, et al. Cancer Immunol Res (2020) pmid: 32321774
72. Hakimi AA, et al. Nat Commun (2020) pmid: 32820162
73. Miao D, et al. Nat. Genet. (2018) pmid: 30150660
74. Yang Q, et al. Ann Transl Med (2021) pmid: 33850862
75. Varela I, et al. Nature (2011) pmid: 21248752
76. Fujimoto A, et al. Nat Commun (2015) pmid: 25636086
77. Jiao Y, et al. Nat. Genet. (2013) pmid: 24185509
78. Churi CR, et al. PLoS ONE (2014) pmid: 25536104
79. Simbolo M, et al. Oncotarget (2014) pmid: 24867389
80. Nature (2014) pmid: 24476821
81. Robertson AG, et al. Cell (2017) pmid: 28988769
82. Pietzak EJ, et al. Eur. Urol. (2017) pmid: 28583311
83. Williams EA, et al. Acta Neuropathol. (2020) pmid: 32405805
84. Petrini I, et al. Nat. Genet. (2014) pmid: 24974848
85. Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878
86. da Costa WH, et al. BJU Int. (2014) pmid: 24053427
87. Pawłowski R, et al. Int. J. Cancer (2013) pmid: 22949125
88. Hakimi AA, et al. Eur. Urol. (2013) pmid: 23036577
89. Numata M, et al. Int. J. Oncol. (2013) pmid: 23229642
90. Hakimi AA, et al. Clin. Cancer Res. (2013) pmid: 23620406
91. Peña-Llopis S, et al. Nat. Genet. (2012) pmid: 22683710
92. Kapur P, et al. Lancet Oncol. (2013) pmid: 23333114
93. Lemon B, et al. Nature () pmid: 11780067
94. Xia W, et al. Cancer Res. (2008) pmid: 18339845
95. Hopson S, et al. ACS Chem. Biol. (2017) pmid: 28921948
96. Porter EG, et al. J. Biol. Chem. (2017) pmid: 28053089
97. Niimi A, et al. Mutat. Res. (2015) pmid: 26117423
98. Brownlee PM, et al. Cell Rep (2014) pmid: 24613357
99. Kakarougkas A, et al. Mol. Cell (2014) pmid: 25066234
100. Gao W, et al. Proc. Natl. Acad. Sci. U.S.A. (2017) pmid: 28082722
101. DiNardo CD, et al. N. Engl. J. Med. (2018) pmid: 29860938
102. Lowery MA, et al. Lancet Gastroenterol Hepatol (2019) pmid: 31300360
103. Abou-Alfa GK, et al. Lancet Oncol. (2020) pmid: 32416072
104. Mellinghoff IK, et al. J. Clin. Oncol. (2020) pmid: 32530764
105. Zhu AX, et al. JAMA Oncol (2021) pmid: 34554208